Wahl Discusses Game Changing FDA-Approved Prostate Cancer Therapy

Richard L. Wahl, MD, director of Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis, sat down with Fox 5 DC to discuss how recent advancements in nuclear medicine could be a game-changer for identifying and treating disease like prostate cancer. Wahl, a nuclear medicine expert and current president of the Society of Nuclear Medicine and Molecular Imaging, says the new FDA-approved PET imaging agent PyL is able to detect tiny cancer foci, which could help better physicians’ ability to find the cancer and recommend appropriate therapy treatments.